Compare HubSpot Inc (HUBS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Organon & Co. Common Stock — how do they compare? HubSpot Inc trades at $226.2 (market cap $11.03B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: HubSpot Inc is far larger — about 3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Organon & Co. Common Stock for 0 Days on average.
| HUBS | OGN | |
|---|---|---|
Market Cap | $11.03B | $3.62B |
Volume | 784,639 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $494.58 | $13.81 |
52-Week Low | $170.39 | $5.70 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $9.93B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $226.23, up 1.28% today, with a neutral technical signal and strong fundamental growth. The stock has beaten earnings estimates for the last three quarters, with revenue growing from $1.7B in 2022 to $3.1B in 2025. Recent news highlights an AI-focused strategy and partnership with OpenAI, aiming to boost margins and customer outcomes.
The outlook is positive with 55% analyst buy ratings and a $244.09 consensus price target, suggesting 8% upside. Key risks include high valuation multiples and competitive pressures in the SaaS space. Cash flow growth and institutional accumulation support the bullish case, but investors should monitor execution of AI initiatives and margin targets.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
